Comparative Pharmacology
Head-to-head clinical analysis: BRETYLIUM TOSYLATE versus SOTALOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETYLIUM TOSYLATE versus SOTALOL HYDROCHLORIDE.
BRETYLIUM TOSYLATE vs SOTALOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bretylium tosylate is a class III antiarrhythmic agent that prolongs the action potential duration and refractory period by blocking potassium channels. It also initially causes norepinephrine release, leading to transient hypertension and increased contractility, followed by adrenergic neuron blockade, resulting in hypotension and reduced contractility.
Sotalol is a non-selective beta-adrenergic receptor antagonist (beta-blocker) with additional class III antiarrhythmic activity (prolongation of cardiac action potential duration via blockade of potassium channels). It decreases heart rate, myocardial contractility, and AV conduction velocity, and increases ventricular refractoriness.
For ventricular tachycardia/fibrillation: 5-10 mg/kg IV bolus over 1-2 minutes, may repeat every 15-30 minutes up to 30 mg/kg total. Maintenance: 5-10 mg/kg IV every 6 hours or 0.5-2 mg/min continuous infusion. Intramuscular: 5-10 mg/kg undiluted, may repeat every 1-2 hours.
Initial: 80 mg orally twice daily; may increase every 3 days to 160-320 mg/day, maximum 640 mg/day (for life-threatening arrhythmias). Also available as 80 mg intravenous over 20 minutes (1.5 mg/kg) for acute management.
None Documented
None Documented
5-10 hours; prolonged in renal impairment (up to 30 hours)
Terminal elimination half-life: 10-20 hours in normal renal function; prolonged in renal impairment (up to 40 hours), requiring dose adjustment.
Renal: ~80% unchanged; biliary/fecal: <1%
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <20%.
Category C
Category A/B
Antiarrhythmic (Class III)
Antiarrhythmic (Class III)